Table 1 Characteristics of AML patients and experiments
Pt No | Source | % Blasts | Disease status | Molecular mutation | Cytogenetic | Experiments |
|---|---|---|---|---|---|---|
1 | BM | 86 | New diagnosis | IDH1 + TET2 | 46,XX | Chi |
2 | BM | 71 | New diagnosis | Negative | 46,XY | Chi |
3 | BM | 92 | Relapse/refractory | FLT3-ITD | Complex | Chi |
4 | BM | 65 | New diagnosis | Negative | t(8;21) | Chi |
5 | BM | 46 | New diagnosis | Kit D816 | t(8;21) | Chi |
6 | BM | 77 | Relapse | Negative | Complex | Chi + ADM |
7 | BM | 63 | New diagnosis | NPM1 + DNMT3a | 46,XY | Chi + ADM |
8 | BM | 90 | New diagnosis | FLT3-ITD + NPM1 | Complex | Chi + ADM |
9 | BM | 74 | New diagnosis | Negative | Inv(16) | Chi + ADM |
10 | BM | 59 | Relapse/refractory | FLT3-ITD + DNMT3a | 46,XY | Chi + ADM |
11 | BM | 81 | Relapse | Negative | 47,XX, + 8 | Chi + ADM |